Name | GW-766994 |
---|---|
Synonyms |
4-{[({[(2S)-4-(3,4-Dichlorobenzyl)-2-morpholinyl]methyl}carbamoyl)amino]methyl}benzamide
Z6213K1TPE Benzamide, 4-[[[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]- GW-766994 |
Description | GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis. |
---|---|
Related Catalog | |
Target |
CCR3:7.86 (pKi) |
In Vitro | GW 766994 is a specific chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis[1]. GW 766994 (10 μM) reverses CCL11-induced activation of CDK5, phosphorylations of CDK5, GSK3β, and increased phosphorylation of tau in hippocampal neurons[2]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 685.8±55.0 °C at 760 mmHg |
Molecular Formula | C21H24Cl2N4O3 |
Molecular Weight | 451.346 |
Flash Point | 368.5±31.5 °C |
Exact Mass | 450.122559 |
LogP | 1.50 |
Vapour Pressure | 0.0±2.1 mmHg at 25°C |
Index of Refraction | 1.608 |
Storage condition | 2-8℃ |